EMERCell Receives Strategic Investment from Onward Therapeutics

– Onward Therapeutics from Montpellier, France, invested in EMERCell.
– The amount of the deal was not disclosed.
– EMERCell SAS is a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
– Onward Therapeutics became the majority shareholder after it invested in EMERCell SAS.